Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS203 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
JS203 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone is a combination therapy being developed by Shanghai Junshi Bioscience Co., Ltd. for the treatment of various B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). The regimen combines JS203, a bispecific antibody targeting CD20 on B-cells and CD3 on T-cells, with the standard-of-care R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). JS203 is designed with a lower affinity for CD3 to potentially improve the safety profile while maintaining anti-tumor activity by recruiting T-cells to kill CD20-expressing malignant B-cells. The combination is currently being evaluated in Phase I/II clinical trials in China.
- Other names
- JS203 + R-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on JS203 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS203 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.